L-R: Brian Morrissey, General Manager, Michael Gately, Head of Operations and Declan Hoare, Head of Quality meet with the ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Leqselvi (deuruxolitinib), made by Sun Pharma UK, as a treatment for severe alopecia areata in adults. Alopecia areata is a ...

Inizio Ignite has made five appointments to its key leadership amid the unification of four teams, Research Partnership, ...

Incyte Biosciences UK’s Opzelura (ruxolitinib) cream has been approved for reimbursement for eligible patients with ...

As AI drives seismic change across the pharmaceutical industry, its adoption is accompanied by uncertainty and risk.

Bristol Myers Squibb’s (BMY) Sotyktu has been approved by the US FDA to treat adults with active psoriatic arthritis (PsA). The approval is based on positive results from two phase 3 trials (POETYK ...

Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical and biotech clients to ...

Medical Affairs is operating at a pivotal moment. Expectations have expanded rapidly – deeper scientific exchange, sharper ...

Johnson & Johnson (J&J) has announced US FDA approval for Tecvayli (teclistamab-cqyv) plus Darzalex Faspro (daratumumab and hyaluronidase-fihj) to treat adults with relapsed or refractory multiple ...

There’s a clear gap: output is rising, but engagement isn’t. This often happens because many strategies focus on HCPs’ ...

The last patient in Lundbeck’s phase 3 clinical trial, MASCOT, has been randomised ahead of schedule in a study evaluating amlenetug as a potential treatment for multiple system atrophy (MSA). The ...

Johnson & Johnson’s (J&J) nipocalimab, a potential immunoselective investigational treatment for adults with systemic lupus ...